Global Polymerase Chain Reaction (PCR) for qPCR, dPCR, Singleplex & Multiplex Markets, 2023-2024 and 2027: Disruption Looms, Syndromic Diagnostics Looks Unstoppable, The Instrumentation Curve | ResearchAndMarkets.com

PCR Markets

Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027″ report has been added to ResearchAndMarkets.com’s offering.

The report forecasts the market size over five years with the only analysis available that breaks out Singleplex and Multiplex testing markets.

COVID-19 Diagnostics

COVID-19 Diagnostics is driving PCR into a dominant technology role and spurring the growth of new PCR based technologies. Will thermal cycling become obsolete? Are singleplex tests going to be obsolete? Will routine respiratory screening become a reality? Will diagnostics move into the Physician’s Office or even the Home? Will digital PCR become the new lab standard?

New Generation of PCR

PCR has proved itself in the market. And the new generation of PCR, digital PCR promises to keep that success going. Driven even faster by the huge demand for pandemic diagnostics. New levels of sensitivity have implications for Liquid Biopsy and Cancer Screening markets.

Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success.

Make investment decisions and valuations with confidence using the latest data.

Key Topics Covered:

1 Market Guides

1.1 Situation Analysis

1.2 Guide for Executives and Marketing Staff

1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition

2.1 What are PCR Technologies?

2.2 PCR and Syndromic Testing

2.3 Market Definition

2.3.1 Market Size

2.3.2 Currency

2.3.3 Years

2.4 Methodology

2.4.1 Methodology

2.4.2 Sources

2.4.3 Authors

2.5 Perspective: Healthcare and the IVD Industry

2.5.1 Global Healthcare Spending

2.5.2 Spending on Diagnostics

2.5.3 Important Role of Insurance for Diagnostics

3 PCR – Guide to PCR Technologies

3.1 Concepts

3.1.1 Method

3.2 Applications

3.2.1 Finding Specific DNA

3.2.2 Measuring DNA

3.2.3 Medical and Diagnostic Applications

3.2.3.1 Carrier, prenatal and tissue typing

3.2.3.2 Cancer Diagnosis and Management

3.2.3.3 Infectious Disease – New Levels of Accuracy and Sensitivity

3.2.3.4 Forensic Applications

3.2.3.5 Science and Research

3.3 PCR – Advantages and Disadvantages

3.4 Different Types of PCR

3.4.1 Simple Changes

3.4.1.1 Multiplex-PCR

3.4.1.2 VNTR PCR

3.4.1.3 Asymmetric PCR

3.4.1.4 Long PCR

3.4.1.5 Nested PCR

3.4.1.6 Quantitative PCR

3.4.1.7 Hot-start PCR

3.4.1.8 Touchdown PCR

3.4.1.9 Assembly PCR

3.4.1.10 Colony PCR

3.4.1.11 Suicide PCR

3.4.1.12 Cold PCR

3.4.2 Digital PCR

3.4.2.1 Droplet Digital PCR

3.4.2.2 Comparison between dPCR and Real-Time PCR (qPCR)

3.4.2.3 Digital PCR in Use

3.4.2.4 Digital PCR Commercial History

3.4.3 Isothermal PCR

4 Industry Overview

4.1 Players in a Dynamic Market

4.1.1 Academic Research Lab

4.1.2 Diagnostic Test Developer

4.1.3 Instrumentation Supplier

4.1.4 Chemical/Reagent Supplier

4.1.5 Pathology Supplier

4.1.6 Independent Clinical Laboratory

4.1.7 Public National/regional Laboratory

4.1.8 Hospital Laboratory

4.1.9 Physicians Office Lab (POLS)

4.1.10 Audit Body

4.1.11 Certification Body

5 Market Trends

5.1 Factors Driving Growth

5.1.1 A New Standard

5.1.2 Down the Curve We Go

5.1.3 Multiplexing

5.1.4 Syndromic Diagnostics Looks Unstoppable

5.1.5 The Genetic Blizzard

5.2 Factors Limiting Growth

5.2.1 The Cost Curve

5.2.2 The Other Guys

5.2.3 Systemic Roadblocks

5.3 Diagnostic Technology Development

5.3.1 The Instrumentation Curve

5.3.2 Shifting Role of Diagnostics

5.3.3 Diagnostics Moves Out of the Hospital

5.3.4 Disruption Looms

5.3.5 The Next Five Years

6 PCR Recent Developments

6.1 Recent Developments – Importance and How to Use This Section

6.1.1 Importance of These Developments

6.1.2 How to Use This Section

6.2 Multiplex Meningitis/Encephalitis Panel Market Expanding

6.3 Sensible Dx to Launch 10-Minute POC PCR System

6.4 ReadyGo Dx Plans to Make MDx Testing Easy

6.5 Transformative Biotech Acquires Summit Biolabs’ PCR Tech

6.6 Visby Medical POC STI Multiplex Test Cleared

6.7 Sherlock Biosciences Buys Sense Biodetection

6.8 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx

6.9 HealthTrackRx Investing in Rapid Turnaround Times

6.10 LEX Dx Developing Ultra-Fast Low-Cost PCR

6.11 Next-Gen Dx Technologies Face Uncertain Future

6.12 Rover Dx Developing All-Optical Rapid POC qPCR Platform

6.13 ProtonDx Plans Rapid Molecular Dx Instrument

6.14 Innova Medical Group Licenses MDx Tech

6.15 MicroGEM to Grow Market for 30-Minute RT-PCR System

6.16 Precipio Receives CE-IVD Mark for Cancer Panels

6.17 Siemens Healthineers to Develop Next-Gen MDx Platform

6.18 New York State Approves Enzo Biochem HPV Molecular Test

6.19 Grip Molecular Developing Biosensor Panel to Detect Respiratory Infections

6.20 Co-Diagnostics Seeks EUA for At-Home PCR Diagnostic System

6.21 Chelex-Based Protocol to Reduce Cost, Time for PCR Testing

6.22 Finnish Firms to Form Point-of-Care Testing Firm

6.23 Visby Medical Scales Up Handheld PCR Test for STIs

6.24 DnaNudge Raises $60M

6.25 Roche Reports Diagnostics Revenue Up 51 Percent

6.26 BforCure Preparing Multiple ID Panels for PoC qPCR Platform

6.27 Enzo Biochem, CLX Health Partner for C19 Testing for Travel

6.28 Bio Molecular Systems Gets Approval for Portable PCR Cycler

6.29 Roche Acquires GenMark

6.30 Handheld qPCR Devices Close to Commercialization

6.31 Nuclein Closes $14M in Funding

6.32 WuXi Diagnostics Closes $150M Series B Financing Round

6.33 Visby Medical to develop rapid Flu-COVID PCR test

6.34 Thermo Fisher to acquire Mesa Biotech

6.35 Scope Fluidics Secures €6.2M Supporting Rapid MDx

6.36 SARS- Testing Demand to Continue ‘Through 2022, and Beyond’

6.37 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection

6.38 Fluidigm Saliva Test for SARS-CoV-2 Uses Extraction-free RT-PCR

6.39 Visby Medical Gonorrhea Test Wins $19M AMR Diagnostic Competition

7 Profiles of Key PCR Companies

  • Abacus Diagnostica
  • Abbott Laboratories
  • Accelerate Diagnostics
  • Ador Diagnostics
  • ADT Biotech
  • Agilent/Dako
  • Akonni Biosystems
  • Alveo Technologies
  • Amoy Diagnostics Co., Ltd.
  • Anatolia Geneworks
  • Applied BioCode
  • Applied DNA Sciences
  • Aurora Biomed
  • Aus Diagnostics
  • AVIVA Systems Biology
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bosch Healthcare Solutions GmbH
  • Bruker
  • Caris Molecular Diagnostics
  • Cepheid (Danaher)
  • Credo Diagnostics Biomedical
  • CTK Biotech
  • Cue Health
  • Curetis N.V./Curetis GmbH
  • Diagenode Diagnostics
  • Diasorin S.p.A
  • Eiken Chemical
  • Enzo Biochem
  • Eurofins Scientific
  • Fluxergy
  • Fujirebio
  • Genetic Signatures
  • GenMark Dx (Roche)
  • Greiner Bio-One
  • Hibergene Diagnostics
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • LightDeck Diagnostics
  • Luminex Corp (DiaSorin)
  • LumiraDx
  • Maxim Biomedical
  • Meridian Bioscience
  • Mesa Biotech (Thermo Fisher)
  • Millipore Sigma
  • Minute Molecular
  • Mobidiag (Hologic)
  • Molbio Diagnostics
  • Nanomix
  • NGeneBio
  • Novacyt
  • Operon
  • Panagene
  • Perkin Elmer
  • Precipio
  • Primerdesign (Novacyt)
  • Promega
  • Prominex
  • Qiagen
  • QuantuMDx
  • QuidelOrtho
  • Randox Toxicology
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Scope Fluidics
  • SD Biosensor
  • Seegene
  • Siemens Healthineers
  • SkylineDx
  • Sona Nanotech
  • SpeeDx
  • Standard BioTools
  • Stilla Technologies
  • T2 Biosystems
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics
  • Veramarx
  • Veredus Laboratories
  • Vircell
  • Visby Medical
  • XCR Diagnostics
  • YD Diagnostics
  • Zhejiang Orient Gene Biotech

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”